The dramatic improvement in financials, fueled by non-dilutive collaboration revenue and a strong cash runway, reduces near-term financing risk and supports sustained R&D advancement. Traders should monitor upcoming preclinical updates and IND submissions for CNTY-813 and CNTY-308 as key catalysts.
Price Chart
Executive Summary
Century Therapeutics reported full-year 2025 financial results, highlighted by a significant reduction in net loss to $9.6 million from $126.6 million in 2024, driven by $109.2 million in collaboration revenue from Bristol-Myers Squibb. The company also announced a $135 million private placement in January 2026, extending its cash runway into Q1 2029, and provided updates on advancing its lead programs CNTY-813 (type 1 diabetes) and CNTY-308 (CAR-iT cell therapy) toward clinical entry in 2026–2027.
Key Financial Metrics
Key Facts
- Net loss narrowed to $9.6 million in 2025 from $126.6 million in 2024 due to $109.2 million in collaboration revenue from Bristol-Myers Squibb.
- Cash, cash equivalents, and marketable securities totaled $117.1 million as of December 31, 2025; post-year-end $135 million private placement extends cash runway into Q1 2029.
- R&D expenses decreased to $95.7 million in 2025 from $107.2 million in 2024, reflecting cost discipline.
- CNTY-813, the lead program for type 1 diabetes, is on track for IND submission in Q4 2026 and initial clinical data expected in H2 2027.
- CNTY-308, a CD19-targeted CAR-iT cell therapy, is advancing toward clinical entry in 2026.
Financial Impact
Collaboration revenue surged from $6.6M to $109.2M YoY, driving a 92% reduction in net loss. Cash runway extended by ~3 years via $135M financing.
Risk Factors
- Reliance on preclinical data; clinical trials may not replicate animal model results.
- Future funding needs beyond 2029 could lead to dilution.
- Regulatory delays in IND clearance could push back clinical timelines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254565 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.42 (−7.19%) |
Oct 2, 2026 24d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.42 (−7.19%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.42 (−24.87%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.42 (−26.80%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.42 (−27.55%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.42 (+27.55%) |
Jun 16, 2026 18w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.42 (−36.89%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.42 (−34.86%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.42 (−33.02%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.42 (−33.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers